US FDA suggests increased testing of devices affected by Japan earthquake
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has sent a letter to all foreign and domestic medical device establishments affected by Japan's March earthquake and tsunami, asking them to carry out increased sampling and testing of incoming raw materials and components as well as of finished diagnostic and other medical devices prior to product release1.